Dapirolizumab

• Description :

  Dapirolizumab is a monoclonal antibodi against CD40 ligand. Dapirolizumab targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab attenuates systemic lupus erythematosus[1].

• UNSPSC :

  12352203

• Target :

  TNF Receptor

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Apoptosis

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/dapirolizumab.html

• Purity :

  99.66

• Smiles :

  [Dapirolizumab]

• Molecular Weight :

  (145.5 kDa)

• References & Citations :

  [1]Furie RA, et al., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology (Oxford) . 2021 Nov 3;60 (11) :5397-5407.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [1416147-64-2]